Detailed analysis of metastatic colorectal cancer patients who developed cardiotoxicity on another fluoropyrimidine and switched to S-1 treatment (subgroup analysis of the CardioSwitch-study)

Autor: Sampsa Kinos, Helga Hagman, Päivi Halonen, Leena-Maija Soveri, Mary O'Reilly, Per Pfeiffer, Jan-Erik Frödin, Halfdan Sorbye, Eetu Heervä, Gabor Liposits, Raija Kallio, Annika Ålgars, Raija Ristamäki, Tapio Salminen, Maarit Bärlund, Carl-Henrik Shah, Ray McDermott, Rebecka Röckert, Petra Flygare, Johannes Kwakman, Arco Teske, Cornelis Punt, Bengt Glimelius, Pia Österlund

Publikováno v: Acta Oncologica, Vol 63, Iss 1 (2024)

Background and purpose: The CardioSwitch-study demonstrated that patients with solid tumors who develop cardiotoxicity on capecitabine or 5-fluorouracil (5-FU) treatment can be safely switched to S-1, an alternative fluoropyrimidine (FP). In light of

Externí odkaz: https://doaj.org/article/340dd2f28c5441ddaf0adaf8e0022afa

Protein array profiling of circulating angiogenesis-related factors during bevacizumab containing treatment in metastatic colorectal cancer.

Autor: Helga Hagman, Pär-Ola Bendahl, Jon Lidfeldt, Mattias Belting, Anders Johnsson

Publikováno v: PLoS ONE, Vol 13, Iss 12, p e0209838 (2018)

BackgroundProlonged angiogenesis inhibition may improve treatment outcome in metastatic colorectal cancer (mCRC) patients. However, due to the complexity of the angiogenic pathways there is a lack of valid predictive biomarkers for anti-angiogenic ag

Externí odkaz: https://doaj.org/article/37d0e001fba24459b4387a1fba2a0fde

[Liver transplantation optional treatment of liver metastases from colorectal cancer]

Autor: Per, Lindnér, Helga, Hagman, Gunnar, Söderdahl

Publikováno v: Lakartidningen. 117

Surgical treatment of liver metastases from colorectal cancer (CLM) is the only treatment option with curative potential; however, only about 15% to 20% of the patients seen at major hospitals are candidates for surgical resection. In a prospective s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::c37dd288c390f67e452d36ee027d09f3
https://pubmed.ncbi.nlm.nih.gov/32314327

A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial

Autor: Jan-Erik Frödin, Eva Fernebro, Anders Johnsson, J. Sundberg, Åke Berglund, Maria Albertsson, Lene Weber Vestermark, Helga Hagman

Publikováno v: Hagman, H, Frödin, J-E, Berglund, Å, Sundberg, J, Weber Vestermark, L, Albertsson, M, Fernebro, E & Johnsson, A 2016, ' A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer : the Nordic ACT2 trial ', Annals of Oncology, vol. 27, no. 1, pp. 140-147 . https://doi.org/10.1093/annonc/mdv490

BACKGROUND: Maintenance treatment (mt) with bevacizumab (bev) ± erlotinib (erlo) has modest effect after induction chemotherapy in metastatic colorectal cancer (mCRC). We hypothesized the efficacy of erlo to be dependent on KRAS mutational status an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97be907dd1a2d2b0a9b6c35744a8913f
https://doi.org/10.1093/annonc/mdv490

Feasibility of switching to S-1 after other fluoropyrimidine-related cardiotoxicity during chemotherapy for solid tumors

Autor: Gabor Liposits, Raymond S. McDermott, Raija Kallio, Halfdan Sorbye, Bengt Glimelius, Johannes J.M. Kwakman, Annika Ålgars, Erik van Werkhoven, T. Salminen, Rebecka Röckert, Petra Flygare, Cornelis J. A. Punt, Helga Hagman, Eetu Heervä, Per Pfeiffer, P. Halonen, L. M. Soveri, Sampsa Kinos, Carl-Henrik Shah, Pia Österlund

Publikováno v: Österlund, P, Kinos, S, Halonen, P, Soveri, L-M, Kwakman, J J, Salminen, T, McDermott, R S, Pfeiffer, P, Heervä, E, Istvan Liposits, G, Röckert, R, Ålgars, A, Kallio, R S, Sorbye, H, Flygare, P, Hagman, H, Shah, C-H, Werkhoven, E D V, Glimelius, B, Punt, C J A & Cardioswitch Group 2020, ' Feasibility of switching to S-1 after other fluoropyrimidine-related cardiotoxicity during chemotherapy for solid tumors. ', Journal of Clinical Oncology, vol. 38, no. 15 Suppl., pp. 7037 . https://doi.org/10.1200/jco.2020.38.15_suppl.7037

7037 Background: Fluoropyrimidines (FP) are the cornerstone of chemotherapy in many solid tumors and linked to cardiotoxicity (CarTx) in about 5% (Polk, Cancer Treat Rev 2013), often leading to FP discontinuation. CarTx may be less common with S-1 an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a2687921bc5fce0128f6fa74dcbc3bc
https://doi.org/10.1200/jco.2020.38.15_suppl.7037